PETALING JAYA: Duopharma Biotech Bhd
posted a net profit of RM88.56mil in the nine-month period to Sept 30, 2026 (9M26), as compared to RM68.42mil in the year-ago period, due to strong profit margins that offset a weaker topline.
According to the pharmaceutical group’s results filing with Bursa Malaysia, profit margins were supported by a more favourable product mix and lower imported active pharmaceutical ingredient costs amid the strengthening of the ringgit.
Revenue in 9M26 was RM692.29mil, down from RM707.01mil in 9M25, primarily attributable to the normalisation of public sector insulin sales following the exceptional sales recorded in the first half of 2025.
In the third quarter alone, the group recorded a higher net profit of RM27.98mil as compared to RM22.57mil in the year-ago quarter. Quarterly revenue dipped to RM210.05mil from RM222.49mil in the previously comparative quarter.
